It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
High dose-rate brachytherapy is a treatment technique for gynecologic cancers where intracavitary applicators are placed within the patient’s pelvic cavity. To ensure accurate radiation delivery, localization of the applicator at the time of insertion is vital. This study proposes a novel method for acquiring, registering, and fusing three-dimensional (3D) trans-abdominal and 3D trans-rectal ultrasound (US) images for visualization of the pelvic anatomy and applicators during gynecologic brachytherapy. The workflow was validated using custom multi-modal pelvic phantoms and demonstrated during two patient procedures. Experiments were performed for three types of intracavitary applicators: ring-and-tandem, ring-and-tandem with interstitial needles, and tandem-and-ovoids. Fused 3D US images were registered to magnetic resonance (MR) and computed tomography (CT) images for validation. The target registration error (TRE) and fiducial localization error (FLE) were calculated to quantify the accuracy of our fusion technique. For both phantom and patient images, TRE and FLE across all modality registrations (3D US versus MR or CT) resulted in mean ± standard deviation of 4.01 ± 1.01 mm and 0.43 ± 0.24 mm, respectively. This work indicates proof of concept for conducting further clinical studies leveraging 3D US imaging as an accurate, accessible alternative to advanced modalities for localizing brachytherapy applicators.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Western University, Department of Medical Biophysics, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884); Robarts Research Institute, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884)
2 Robarts Research Institute, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884)
3 University of Waterloo, Department of Physics and Astronomy, Waterloo, Canada (GRID:grid.46078.3d) (ISNI:0000 0000 8644 1405)
4 Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Department of Radiation Oncology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
5 University of Manitoba, Department of Physics and Astronomy, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
6 Verspeeten Family Cancer Centre, London, Canada (GRID:grid.21613.37)
7 Western University, Department of Medical Biophysics, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884); Verspeeten Family Cancer Centre, London, Canada (GRID:grid.39381.30); Western University, Department of Oncology, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884)